Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human autologous 3D-DCob cell therapy for alveolar bone atrophy
jRCTb060260029Phase 1Recruiting
- Sponsor
- Hiroshima University
- Start
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Alveolar bone atrophy (ABL), sponsored by Hiroshima University. Primary endpoint: Safety. Started Jun 2026; status: recruiting.
02
Conditions
Alveolar bone atrophy (ABL)
Beyond the preview
Go deeper on jRCTb060260029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb060260029.